Company Information
CIN
Status
Date of Incorporation
09 March 1989
State / ROC
Hyderabad / ROC Hyderabad
Last Balance Sheet
31 March 2023
Last Annual Meeting
05 August 2023
Paid Up Capital
218,073,717
Authorised Capital
300,000,000
Directors
Venkateswarlu Jasti
Director/Designated Partner
over 2 years ago
over 2 years ago
Santanu Mukherjee
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Sudharani Jasti
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Subbarao Jasti
Beneficial Owner
about 6 years ago
about 6 years ago
Gopala Krishna Muddusetty .
Director/Designated Partner
over 6 years ago
over 6 years ago
Seyed Ehtesham Hasnain
Authorised Representative
over 15 years ago
over 15 years ago
Past Directors
Kukudala Ravi
Deputy Nodal Officer
over 6 years ago
over 6 years ago
Ananthasai Padmaja Jasthi
Additional Director
about 7 years ago
about 7 years ago
Subba Rao Parupalli
Cfo(kmp)
almost 11 years ago
almost 11 years ago
Govinda Prasad Dasu
Director
about 16 years ago
about 16 years ago
K V Raghavan
Director
about 19 years ago
about 19 years ago
Ramachandra Prasad Tata
Director
about 20 years ago
about 20 years ago
Hanumantha Rao Kokkonda
Company Secretary
almost 25 years ago
almost 25 years ago
Rangaswamy Naidu Maripuri
Director
about 27 years ago
about 27 years ago
Patents
ABSTRACT
“MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS”
The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention...
The present invention provides an improved process for the preparation of Ferric carboxymaltose (FCM) complex. In this process the oxidation of maltodextrins are carried out by using peroxide in the presence of sodium tungstate catalyst and later complex formation with ferric hydroxide or iron hydroxide maltodextrin...
A process suitable for adoption to large scale manufacture of l-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-l-piperazinyl)methyl]-lH-indole dimesylate monohydrate, which is a selective 5-HT6 receptor antagonist intended for the symptomatic treatment of Alzheimer"s disease and other disorders of memory...
Abstract of the Invention
The present invention provides novel crystalline Form of Nintedanib and process for its preparation. The present invention also provides to a novel process for the preparation of Nintedanib. The present invention further provides to novel intermediates used in the preparation of Nintedanib...
The present invention relates to a process for the preparation of optically active alkyl amine
compounds
Abstract
AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS
The present invention relates to compounds of formula (I), including their stereoisomers and pharmaceutically acceptable salts. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The comp...
The present invention relates to novel sulfone compounds as 5-HT6 receptor ligands of the formula (I), and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them.
The present invention also r...
The present invention provides an improved process for the preparation of Ferric carboxymaltose (FCM) complex. In this process the oxidation of maltodextrins are carried out by using an organic hypo halite in the presence of a catalyst and a phase transfer catalyst and later complex formation with ferric salt or fer...
ABSTRACT
The present invention relates to topical spray compositions and methods for the preparation of the same. The topical spray composition comprising Glycopyrrolate or its salts with specific class of excipients may be used to reduce various secretions in human body, specifically to control hyperhydrosis.
...
The present invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them.
Formula
The present invention also relates to a process for the preparation of above said novel compounds, and their pharmaceutically acceptable salts.
The compound...
Abstract
The present invention provides an improved process for the preparation of Ferric carboxymaltose (FCM) complex. In this process the oxidation of maltodextrins are carried out by using peroxide in the presence of sodium tungstate catalyst and later complex formation with ferric hydroxide or iron hydroxide ...
The present invention relates to novel quinoline compounds of formula (I), and their pharmaceutically acceptable salts and process for their preparation.
The compounds of formula (I) are useful in the treatment of various disorders that are related to 5-HT4 receptor agonists.
The present invention relates to compound of formula (I), or stereoisomers and pharmaceutically acceptable salts as muscarinic MI receptor positive allosteric modulators. This invention also relates to methods of makirig such compounds and pharmaceutical compositions comprising such compounds. The compounds of this ...
The present invention relates to novel intermediates of Bruton’s Tyrosine Kinase inhibitor. The present invention particularly relates to novel intermediates of Ibrutinib and PCI-29732. The present invention more particularly relates to an improved process for the preparation of the intermediates which is commercial...
Abstract
“PROCESS FOR THE PREPARATION OF ROSUVASTATIN CALCIUM AND PREPARATION OF ITS NOVEL INTERMEDIATES”
The present invention relates to process for the preparation of 7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N- methylsulfonylamino)pyrimidin-5-yl]-(3R,5S)-dihydroxy-(E)-6-heptenoic acid calcium having form...
ABSTRACT;
“PHARMACEUTICAL COMPOSITIONS OF 5-HT6 ANTAGONIST”
The present invention relates to an immediate release (IR) pharmaceutical composition comprising 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl) methyl]-1H-indole or pharmaceutically acceptable salt (s) and one or more pharmaceutically...
A Process for the preparation of water soluble trivalent iron carbohydrate complex having a weight average molecular weight of 80 kDa to 400 kDa obtainable from oxidation of maltodextrins using organic hypohalite.
The present invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them.
The present invention also relates to a process for the preparation of above said novel compounds, and their pharmaceutically acceptable salts.
The compounds of formu...
The present invention relates to novel acrylamide compounds of formula (I), and their pharmaceutically acceptable salts and process of their preparation.
The compounds of formula (I) are useful in the treatment of various disorders that are related to Histamine H3 receptors.
The invention relates to Novel Z form of ENTACAPONE-( Z N,N-Diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-acrylamide) of the formula 1
from pure 3- O- alkylated Entacapone of the formula (7)
by treating with aluminium chloride and pyridine with dichloromethane as solvent to get crude Ent...
The present invention relates to novel aminoalkoxy arylsulfonamide compounds of the formula (I), their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them.
The present invention also relates to a process for the preparation of...
The present invention discloses thioether derivatives of formula (I)along with its stereoisomer or its salt with an inorganic or organic acid, wherein: R1, R3 and R4 independently represents hydrogen, halogen, cyano, (C1-C3)alkyl, halo(C1-C3)alkyl, thio(Ci-C3)alkyl, (C3-C7)cycloalkyl, (Ci-C3)alkoxy, cyclo(C3-C7)alko...
The invention disclosed in this application is related to an improved process for the preparation of losartan.this involves reaction of 2-n-butyl-4-chloro-5-formyl imidazole with 2-(4-bromomethyl)benzonitrile in the phase transfer catalyst and alkali,and the formed cyano aldehyde is reduced to get cyano alcohol.The ...
The improved process for the preparation of Losartan comprises reacting OTBN (Ortho tolyl benzonitrile) with DBDMH (dibromo dimethyl hydantoin) to give 'Bromo OTBN' which is reacted with BCFI in presence of a base and phase transfer catalyst to give 'Cyanoaldehyde' which is in turn reacted with sodium azide in the p...
The present invention relates to an improved process for the preparation of 6-methyl-2-[4-methylphenyl]imidazo[l,2-a]pyridine-3-N,N-dimethyl acetamide having formula (i).
The compound of formula (V) has adopted name "Zolpidem". The present invention also relates to novel intermediate of the formula (2) and a pro...
The present invention relates to the improved process for the preparation of highly pure form of S-[l,2-(dicarbethoxy)-ethyl]O,O-dimethyl phosphorodithioate having formula
(I).
The compound of formula (I) has adopted name "Malathion". The present invention also relates to the novel process of preparing intermedia...
The present invention relates to novel amino arylsulfonamide compounds of the formula (I), their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them:
The present invention also relates to a process for the preparation of above sai...
The present invention relates to a proves for the preparation of compounds described by formula (I)
wherein R1, R2 and R4 independently selected from hydrogen, chloro, fluoro, amino, mtro, cyano, CHO, (C1-C3)alkyl, perhalo(C1-C3)alkyl, (C1-C3)alkoxy, aryl, aralkyl, aralkoxy, (C5- C7)heterocyclyl, (C5-C7)h...
ABSTRACT
4-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL) INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS
The present invention relates to novel 4-(Heterocyclyl)alkyl-N-(arylsulfonyl)indoIe compounds of the formula (I), their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acce...
The present invention relates to novel alpha4 beta2 neuronal nicotinic acetylcholine receptor ligand compounds of the formula (I), and their derivatives, stereoisomers, pharmaceutically acceptable salts and compositions containing them.
The present invention also relates to a process for the preparation of above...
The present invention provides novel functional assay for G protein coupled receptors (GPCRs), by measuring intracellular cyclic adenosine monophosphate (cAMP) levels utilizing reporter gene driven cell based assay. The novel assay provides both binding affinity as well as mode of action of compounds in a single set...
5-(HETER0CYCLYL)ALKYL-N-(ARYLSULF0NYL)IND0LE COMPOUNDS
AND THEIR USE AS 5-HT6 LIGANDS
The present invention relates to novel 5-(Heterocyclyl)alkyl-N-(arylsulfonyl)indole compounds of the formula (I), their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable com...
"NOVEL INTERMEDIATES USEFUL FOR THE PREPARATION OF
ARIPIPRAZOLE AND METHODS FOR THE PREPARATION OF
THE NOVEL INTERMEDIATES AND ARIPIPRAZOLE"
The invention disclosed in this application relates to an improved process for the preparation of aripiprazole (1) which comprises (i) Reacting 6-hydroxy-l-indanone (11) wit...
The present invention describes substituted 3-Aminoalkoxyindoles, compounds of the general formula (I), its stereoisomers, its radioisotopes, its geometric forms, its N-oxides, its polymorphs, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates, its useful bio-active metabolites and any s...
NOVEL INTERMEDIATES, PROCESS FOR THEIR PREPARATION & PROCESS FOR PREPARING METYROSINE USING THE INTERMEDIATES This invention provides an improved process for the preparation of Metyrosine of the formula (1)
by reacting N-BOC-L-alanine of the formula -(24) with a compound of formula-(25)
Wherein Rl to R5 represent...
The present invention relates to heterocyclyl compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them.
The present invention also relates to a process for the preparation of above said novel compounds, and their- pharmaceutically acceptable salts.
The compounds of ...
Abstract
The present invention relates to novel aryl indolyl sulfonamide compounds of the formula (1),
their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates described herein and pharmaceutically acceptable compositions con...
Abstract
The present invention relates to novel aryl sulfonamide amine compounds of the formula (I), their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates described herein and pharmaceutically acceptable compositions contai...
The present invention describes substituted 3-Aminoalkoxyindoles, compounds of the general formula (I), its stereoisomers, its radioisotopes, its geometric forms, its N-oxides, its polymorphs, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates, its useful bio-active metabolites and any s...
The present invention describes substituted 3-Aminoalkoxyindoles, compounds of the general formula (I), its stereoisomers, its radioisotopes, its geometric forms, its N-oxides, its polymorphs, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates, its useful bio-active metabolites and any s...
The present invention describes substituted 3-Aminoalkoxyindoles, compounds of the general formula (I), its stereoisomers, its radioisotopes, its geometric forms, its N-oxides, its polymorphs, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates, its useful bio-active metabolites and any s...
The present invention describes substituted 3-Aminoalkoxyindoles, compounds of the general formula (I), its stereoisomers, its radioisotopes, its geometric forms, its N-oxides, its polymorphs, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates, its useful bio-active metabolites and any s...
NOVEL SUBSTITUTED INDOLYL COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS
The present invention relates to novel substituted indolyl compounds of the formula (I), their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them.
The present in...
The present invention relates to an improved process for the preparation of (4S,6S)-4-(ethylamino)-5,6-dihydro-6-methyl-4H-thieno[2,3-b]thiopyran-2-sulfonamide-7,7-dioxide hydrochloride having formula 1.
The compound of formula l_ has adopted name "Dorzolamide hydrochloride". Dorzolamide hydrochloride is prepare...
The present invention relates to novel bicyclic compounds of the formula (I), and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them.
The present invention also relates to a process for t...
The present invention describes substituted 3-Aminoalkoxyindoles, compounds of the general formula (I), its stereoisomers, its radioisotopes, its geometric forms, its N-oxides, its polymorphs, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates, its useful bio-active metabolites and any s...
The present invention provides carbazole derivatives of formula (I), useful in treatment of a CNS disorders related to or affected by the 5-HT 6 receptor. Phannacological profile of these compounds includes high affinity binding with 5-HT 6 receptor along with good selectivity towards the said receptor. The present ...
The present invention provides a process for the large scale production of 1H-[1,2,3]triazole of formula (I) and it’s intermediate 1-benzyl-1H-[1,2,3]triazole of formula (II) by using benzyl azide and vinyl acetate as starting materials. This process is economical, environment friendly and safer by avoiding use of s...
An improved process for the preparation of l,2-benzisoxazoIe-3-methane sulfonate which is an intermediate useful for the preparation of zonisamide Which comprises (1) reacting methylsalicylate with methane sulfonyl chloride to get sulfonyl derivatives (2) treating it with a strong base to get the correspo...
The present invention relates to a process for the preparation of indole derivatives,particulaerly those, which are useful as pharmaceutical intermediates. The process involves formation derivative between a phenyl hydrazine and a ketone amine, followed by cyclisation 2,3-substituted indole derivative in the presenc...
ABSTRACT
“FLUOROINDOLE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS”
The present invention relates to compound of formula (I), or stereoisomers and pharmaceutically acceptable salts as muscarinic M1 receptor positive allosteric modulators. This invention also relates to methods of makin...
The present invention relates to novel l,2-dihydro-2-oxoquinoline compounds of the formula (I), and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them.
The present invention also relates ...
The present provides arylthioether tryptamine derivatives of formula(1) useful in treatment of a CNS disorder related to or affected by the 5-HT6 receptor pharmacological profile of these compounds includes high affinity binding with 5-HT6 receptor along with good selectivity towards the said receptor. the present i...
The present invention provides aminoaryl sulphonamide derivatives of formula (I), useful in the treatment of a CNS disorder related to or affected by the 5-HT6 receptor. Pharmacological profile of these compounds includes high affinity binding with 5-HT 6 receptor along with good selectivity towards the said recepto...
The present invention relates to pure 5-HT6 receptor antagonist or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to NMDA receptor antagonist and their use in the treatment of cognitive disorders. The invention further relates to the pharmaceutical composition containing the said...
ABSTRACT
COMBINATION OF PURE 5-HT6 RECEPTOR ANTAGONISTS WITH ACETYLCHOLINESTERASE INHIBITORS
The present invention relates to pure 5-HT6 receptor antagonists, or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to acetylcholinesterase inhibitors and their use in the treatment...
ABSTRACT
TRIPLE COMBINATION OF PURE 5-HT6 RECEPTOR ANTAGONISTS, ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONIST
The present invention relates to a combination of pure 5-HT6 receptor antagonist, acetylcholinesterase inhibitor and NMDA receptor antagonist. Also, the present invention provides pure 5...
ABSTRACT
TRIPLE COMBINATION OF HISTAMINE-3 RECEPTOR INVERSE AGONISTS, ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONIST
The present invention relates to a combination of histamine-3 receptor inverse agonist, acetylcholinesterase inhibitor and NMDA receptor antagonist. Also, the present invention pro...
ABSTRACT
COMBINATION OF HISTAMINE-3 RECEPTOR INVERSE AGONISTS WITH ACETYLCHOLINESTERASE INHIBITORS
The present invention relates to the combination of histamine-3 receptor inverse agonist and acetylcholinesterase inhibitor. Also, the present invention provides histamine-3 receptor (H3R) inverse agonist, or th...
ABSTRACT
MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention d...
ABSTRACT
“MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS”
The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention...
ABSTRACT
HETEROARYL COMPOUNDS AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs)....
ABSTRACT
“FLUOROPIPERIDINE COMPOUNDS AS PURE 5-HT6 RECEPTOR ANTAGONITS”
The present invention relates to fluoropiperidine compounds of formula (I), their stereoisomers, isotopic forms or pharmaceutically acceptable salts thereof as 5-HT6 receptor antagonists. In particular the present invention discloses the m...
ABSTRACT
“PRODRUGS OF ABIRATERONE”
The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers, or pharmaceutically acceptable salt (s) thereof as prodrugs of abiraterone. The present invention also describes method of making such compounds, pharmaceutical compositi...
ABSTRACT
“AMORPHOUS PHARMACEUTICAL COMPOSITIONS OF ABIRATERONE ACETATE”
The present invention relates to a pharmaceutical composition comprising solid dispersion of amorphous abiraterone acetate and one or more pharmaceutically acceptable excipients, having improved solubility, stability, bioavailability, and no...
ABSTRACT
The present invention relates to an improved process for the preparation of optically chiral amino compound. The present invention particularly relates to the improved process for the preparation of (S)-1-amino-2,3-dihydro-1H-indene-4-carbonitrile, an important intermediate for the synthesis of ozanimod. T...
The present invention relates to an improved process for the preparation of an anticonvulsant compound, particularly Retigabine or its pharmaceutically acceptable salts and its intermediates which are commercially feasible.
ABSTRACT
“PYRROLO-PYRIDAZINE DERIVATIVES ASMUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS”
The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators...
ABSTRACT
IMPROVED PROCESS FOR PREPARATION OF TBD INTERMEDIATE AND USE THEREOF
The present invention relates to an improved process for the preparation of bicyclic guanidines. The present invention specifically relates to an improved process for the preparation of 1,5,7-Triazobicyclo[4.4.0]dec-5-ene (TBD) compound ...
"HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS"
ABSTRACT
The present invention relates to substituted heterocyclic compounds represented by the general formula (I), or their isotopic forms, stereoisomers, or pharmaceutically acceptable salts thereof. The present invention also describes the method of ...
ABSTRACT
“PYRROLO[1,2-b]-2-PYRIDAZINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS”
The present invention relates to pyrrolo[1,2-b]-2-pyridazinone compounds of formula (I), or their isotopic forms, stereoisomers, or pharmaceutically acceptable salts thereof as 5-HT4 receptor agonists. The present invention also describes...
The present invention relates to heteroalicyclic compounds represented by the general formula (I), or their isotopic forms, stereoisomers, or pharmaceutically acceptable salts thereof. The present invention also describes a method of making such compounds, pharmaceutical compositions comprising such compounds and th...
ABSTRACT
“HETEROAROMATIC COMPOUNDS”
The present invention relates to heteroaromatic compounds of formula (I), or their isotopic forms, stereoisomers, or pharmaceutically acceptable salts thereof as antagonist at serotonin 5-HT2A receptor and agonist at serotonin 5-HT1A receptor. The present invention also describe...
ABSTRACT
N-ARYL BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS
The present invention relates to novel N-aryl benzamide derivatives of formula (I) or an isotopic form, a stereoisomer or a pharmaceutically acceptable salt thereof, as P2X7 receptor antagonist. The present invention also relates to pharmaceutical ...
ABSTRACT
PIPERIDINE SUBSTITUTED COMPOUNDS AS MUSCARINIC M4 RECEPTOR POSITIVE ALLOSTERIC MODULATORS (M4 PAMs)
The present invention relates to piperidine substituted compounds of formula (I), or an isotopic form, a stereoisomer, or a pharmaceutically acceptable salt thereof as muscarinic M4 receptor positive allost...
ABSTRACT
HETEROAROMATIC COMPOUNDS AS MUSCARINIC M4 RECEPTOR POSITIVE ALLOSTERIC MODULATORS (M4 PAMs)
The present invention relates to heteroaromatic compounds of formula (I), or an isotopic form, a stereoisomer, or a pharmaceutically acceptable salt thereof as muscarinic M4 receptor positive allosteric modulat...
ABSTRACT
ORGANIC COMPOUNDS AS MUSCARINIC M4 RECEPTOR POSITIVE ALLOSTERIC MODULATORS (M4 PAMs)
The present invention relates to the compounds of formula (I), or an isotopic form, a stereoisomer, or pharmaceutically acceptable salt thereof as muscarinic M4 receptor positive allosteric modulators (M4 PAMs). The prese...
Registered Trademarks
[Class : 44] Pharmaceutical Consultancy, Pharmacy Advisory Services, Providing Pharmaceutical Information, Consultancy And Information Services Relating To Pharmaceutical Products
[Class : 42] Pharmaceutical Research And Development Services, Research And Development Of Medicines, Laboratory Research Services, Conducting Clinical Trials For Pharmaceuticals, Publication Of The Results Of Clinical Trials For Pharmaceutical Preparations, Drug Discovery
[Class : 35] Wholesale Services In Relation To Pharmaceutical Preparations, Retail Or Wholesale Services For Pharmaceutical, Sanitary Preparations And Medical Supplies
View +2 more Brands for Suven Life Sciences Limited.
Charges
06 December 2012
Bank Of Bahrain And Kuwait Bsc
6 Crore
26 February 1990
State Bank Of India
85 Crore
28 December 1995
State Bank Of India
10 Crore
29 March 1995
State Bank Of India
90 Lak
24 August 2012
Bank Of Bahrain And Kuwait Bsc
30 Crore
17 February 2011
Bank Of India
22 Crore
14 July 2010
State Of Bank Patiala
20 Crore
30 August 2007
State Bank Of India
25 Crore
30 August 2007
State Bank Of India
25 Crore
13 November 1995
Export -- Import Bank Of India
6 Crore
30 December 1997
Industrial Development Bank Of India
6 Crore
22 August 1989
Andhra Pradesh State Financial Corporation
5 Lak
22 October 1990
A.p. State Financial Corporation
32 Lak
01 May 1989
Andhra Pradesh State Financial Corporation
51 Lak
26 February 1990
State Bank Of India
0
01 May 1989
Andhra Pradesh State Financial Corporation
0
13 November 1995
Export -- Import Bank Of India
0
29 March 1995
State Bank Of India
0
22 August 1989
Andhra Pradesh State Financial Corporation
0
06 December 2012
Bank Of Bahrain And Kuwait Bsc
0
14 July 2010
State Of Bank Patiala
0
28 December 1995
State Bank Of India
0
30 December 1997
Industrial Development Bank Of India
0
22 October 1990
A.p. State Financial Corporation
0
24 August 2012
Bank Of Bahrain And Kuwait Bsc
0
17 February 2011
Bank Of India
0
30 August 2007
State Bank Of India
0
30 August 2007
State Bank Of India
0
26 February 1990
State Bank Of India
0
01 May 1989
Andhra Pradesh State Financial Corporation
0
13 November 1995
Export -- Import Bank Of India
0
29 March 1995
State Bank Of India
0
22 August 1989
Andhra Pradesh State Financial Corporation
0
06 December 2012
Bank Of Bahrain And Kuwait Bsc
0
14 July 2010
State Of Bank Patiala
0
28 December 1995
State Bank Of India
0
30 December 1997
Industrial Development Bank Of India
0
22 October 1990
A.p. State Financial Corporation
0
24 August 2012
Bank Of Bahrain And Kuwait Bsc
0
17 February 2011
Bank Of India
0
30 August 2007
State Bank Of India
0
30 August 2007
State Bank Of India
0
Documents
Form AOC-4(XBRL)-03042021_signed
Form DPT-3-22012021-signed
XBRL document in respect Consolidated financial statement-30122020
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-30122020
Optional Attachment-(1)-30122020
Form CHG-4-07122020_signed
Letter of the charge holder stating that the amount has been satisfied-07122020
CERTIFICATE OF SATISFACTION OF CHARGE-20201207
Form GNL-2-03122020-signed
Copy of MGT-8-21112020
Shareholders-MGT_7_R71809818_SHRENIK5462_20201121170158.xlsm
Form MGT-7-21112020_signed
Optional Attachment-(2)-10112020
Optional Attachment-(1)-10112020
Form MGT-14-23102020-signed
Form MGT-6-17102020_signed
Form MR-1-17102020_signed
Copy of board resolution-16102020
Optional Attachment-(1)-16102020
Copy of shareholders resolution-16102020
Copy of letter of consent to act as Managing Director/ Whole time Director/Manager ; -16102020
-16102020
Form MGT-15-07102020_signed
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-07102020
Form MGT-14-25092020-signed
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-08092020
Form MR-1-01062020_signed
Copy of board resolution-01062020
Copy of shareholders resolution-01062020
Copy of letter of consent to act as Managing Director/ Whole time Director/Manager ; -01062020
